NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
EMERYVILLE, Calif., May 04, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018, after the market close, and will host a corporate update conference call and webcast on Wednesday, May 9, 2018, at 4:30 PM Eastern Time.
Conference Call Details
Wednesday, May 9th @ 4:30pm Eastern Time/1:30pm Pacific Time
| Toll Free: | 866-548-4713 |
| International: | 323-794-2093 |
| Conference ID: | 7186111 |
| Webcast: | http://public.viavid.com/index.php?id=129538 |
| Replays, available through May 23rd | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 7186111 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors:
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987
[email protected]
